Stay updated with breaking news from Primary Bone Sarcomas. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
01.08.2023 - Achieved first patient in (FPI) and continuing to enroll CAB-AXL BA3011 in a Phase 2 potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS) Submitted Food & Drug Administration (FDA) meeting request for potentially ...
- Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS)...
- Cleared dose-limiting toxicity observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma cohort readout in 2H23 - Initiated the potentially... | March 23, 2023